J Hypertens:胰岛素抵抗和组织血流量的关系

2015-05-06 MedSci MedSci原创

怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,称子痫前期,或称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。发病率约占全部妊娠的3.9%。子痫前期该疾病的特点是内皮功能障碍、孕妇组织灌注受损,和胰岛素抵抗。Anim-Nyame N等人进行了一项研究,探究子痫前期患者中胰岛素抵抗是否和组织血流量的减少有关。该研究纳入20名子痫前期初产妇,20名在孕妇

怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,称子痫前期,或称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。发病率约占全部妊娠的3.9%。

子痫前期该疾病的特点是内皮功能障碍、孕妇组织灌注受损,和胰岛素抵抗。Anim-Nyame N等人进行了一项研究,探究子痫前期患者中胰岛素抵抗是否和组织血流量的减少有关。

该研究纳入20名子痫前期初产妇,20名在孕妇年龄、孕龄、产次和孕晚期BMI配对的正常孕妇作为对照组。研究者使用静脉闭塞体积描记法比较两组休息小腿肌肉血流量(QaU)。使用空腹血液样本检测两组孕妇血浆胰岛素和葡萄糖的浓度,并计算空腹胰岛素抵抗指数(FIRI),以及两组胰岛素抵抗情况。

研究结果显示,与对照组孕妇(3.94 ± 1.1 QaU)相比,子痫前期组腓肠肌血流量明显减少(1.93 ± 0.86 QaU),, P<0.001。空腹胰岛素浓度和胰岛素抵抗指数子痫前期组明显高于对照组孕妇(P<0.001)。同时研究者发现,子痫前期孕妇休息时小腿血流量和空腹胰岛素浓度(r=-0.57,P =0.008)和空腹胰岛素抵抗指数(FIRI) (r=-0.59,P=0.006)明显相关,但是该相关性并不见于对照组。

研究结果表明,子痫前期孕妇血流量的减少将导致胰岛素抵抗的增加。

原始出处:


Anim-Nyame N, Gamble J, Sooranna SR, Johnson MR, Steer PJ. Relationship between insulin resistance and tissue blood flow in preeclampsia. J Hypertens. 2015. 33(5): 1057-63.

本文系Medsci原创编译整理!转载需要先获得授权,并附原文链接。谢谢!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749548, encodeId=55d51e495484a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 22:16:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038505, encodeId=bfb720385055c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 23 07:16:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075888, encodeId=e1b520e5888b1, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jun 22 05:16:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725828, encodeId=91a61e25828b3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 00:16:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22943, encodeId=0ee522943e9, content=不错哦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 14:05:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2016-01-02 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749548, encodeId=55d51e495484a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 22:16:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038505, encodeId=bfb720385055c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 23 07:16:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075888, encodeId=e1b520e5888b1, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jun 22 05:16:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725828, encodeId=91a61e25828b3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 00:16:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22943, encodeId=0ee522943e9, content=不错哦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 14:05:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749548, encodeId=55d51e495484a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 22:16:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038505, encodeId=bfb720385055c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 23 07:16:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075888, encodeId=e1b520e5888b1, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jun 22 05:16:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725828, encodeId=91a61e25828b3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 00:16:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22943, encodeId=0ee522943e9, content=不错哦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 14:05:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749548, encodeId=55d51e495484a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 22:16:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038505, encodeId=bfb720385055c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 23 07:16:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075888, encodeId=e1b520e5888b1, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jun 22 05:16:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725828, encodeId=91a61e25828b3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 00:16:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22943, encodeId=0ee522943e9, content=不错哦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 14:05:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-09-27 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1749548, encodeId=55d51e495484a, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jan 02 22:16:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038505, encodeId=bfb720385055c, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 23 07:16:00 CST 2015, time=2015-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075888, encodeId=e1b520e5888b1, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jun 22 05:16:00 CST 2015, time=2015-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725828, encodeId=91a61e25828b3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Sep 27 00:16:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22943, encodeId=0ee522943e9, content=不错哦!, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 14:05:00 CST 2015, time=2015-05-08, status=1, ipAttribution=)]
    2015-05-08 qingfengqishi5

    不错哦!

    0

相关资讯

Arthritis Rheumatol:类风湿关节炎患者胰岛素抵抗增加

类风湿关节炎(RA)患者具有胰岛素抵抗(IR)升高现象,但这类患者胰岛素抵抗升高是不与动脉粥样硬化风险增加相关联,相关研究刊登在Arthritis & Rheumatology杂志上。 哥伦比亚大学Jon T. Giles,MD和同事比较95例RA患者和统计学匹配的98名非RA对照组之间IR情况,使用HOMA胰岛素抵抗(HOMA-IR)指数评价胰岛素抵抗程度,HOMA-I

Lancet Diab & Endo:胰岛素抵抗引起的腹部脂肪增生一例

一位44岁女性因腹部脂肪增生就诊我院内分泌科门诊。一年前确诊为2型糖尿病,确诊以来一直使用二甲双胍治疗。既往整体健康状况良好,无胰岛素或其他皮下注射药物使用史。体格检查显示中腹部有两处近乎对称的皮下脂肪团质地样突起物(图A),余未见异常。BMI为29 kg/m²,腰围为104cm。实验室检查显示HbA1c 6%,空腹血糖浓度 6.77 mmol/L,空腹胰岛素浓度 34.38 mU/mL (246

Nature系列综述:脂肪组织和肥胖发生中的microRNA调控网络

近日,来自瑞典卡罗林斯卡学院的Agné Kulyté教授在国际学术期刊nature review endocrinology 发表了一篇综述性文章,详细介绍了在人类脂肪组织以及肥胖过程中发挥重要作用的microRNA调控网络。 microRNA是一类小非编码RNA,具有调节基因表达的功能,因此在不同组织的许多生物学过程中发挥重要作用。miRNA在脂肪组织中的一个主要功能是刺激或抑制脂肪细

JCEM:全身脂肪量和中心脂肪量能独立预测多囊卵巢综合症女性的胰岛素抵抗程度(而不能预测高雄激素血症)

研究背景:肥胖时多囊卵巢综合征(PCOS)患者的一大常见症状。此项研究旨在评估这些患者的体脂分布情况对胰岛素抵抗和雄激素过多的影响。研究设计:根据鹿特丹诊断标准纳入了116位确诊PCOS的高加索女性,对她们进行了临床、体格、激素及代谢指标等的评估。使用双能X线吸收测量法评估全身脂肪量及脂肪分布情况,使用液联质谱及平衡透析的方法检测血清有力睾酮,还使用葡萄糖钳夹技术评估胰岛素敏感性。研究结果:全身脂

Diabetes:儿童体内脂肪组织生物学及功能的早期改变的证据及其与肥胖相关炎症及胰岛素抵抗的关系研究

成人中脂肪细胞的肥大或增生导致肥胖者体内脂肪量的增加,还常与脂肪组织的功能异常有关。本项研究中我们对171名0-18岁的正常和肥胖儿童进行全面综合的研究及临床特征的记录,并评估他们的脂肪组织样本在生物学及功能方面出现了哪些早期改变。 我们的研究发现,从儿童早期即可观察到肥胖者与正常组相比脂肪细胞体积和数量的增加。肥胖儿童脂肪组织组成的改变还伴随着体外实验中基础脂解水平的下降以及基质血管细胞增

Cell Reports:用维生素D治疗糖尿病

二型糖尿病和心脏病常常同时发生,近年来人们发现这两种疾病与维生素D缺乏有关。 慢性炎症会引起胰岛素抵抗和堵塞动脉的斑块,是二型糖尿病和心脏病的根源。华盛顿大学的科学家们发现维生素D能够防止这样的炎症,而且维生素D不足会影响一种关键的免疫细胞。这项研究发表在三月十九日的Cell Reports杂志上。 研究显示,免疫细胞缺乏维生素D受体,会使小鼠抵抗胰岛素的作用,导致体内的葡萄糖过量。